Compare Core Scientific Inc (CORZ) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Invesco Ltd. — how do they compare? Core Scientific Inc trades at $15.41 (market cap $4.94B), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: Invesco Ltd. is far larger — about 2.7× Core Scientific Inc's market cap, and Invesco Ltd. pays a 2.86% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Invesco Ltd. for 77 Days on average.
| CORZ | IVZ | |
|---|---|---|
Market Cap | $4.94B | $13.28B |
Volume | 15,630,800 | 3,698,033 |
Sector | Technology | Financials |
52-Week High | $29.16 | $33.31 |
52-Week Low | $13.57 | $22.44 |
Typical Hold Time | 20 Days | 77 Days |
Enterprise Value | $7.46B | $23.45B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.36, down 3.64% with bearish technical signals despite strong analyst support. The company shows significant financial challenges with a -324.9% net income margin and consecutive quarterly earnings misses, though revenue growth from $319M to $440M is projected. Recent executive appointments and insider buying signal internal confidence amid the company's pivot toward AI data center infrastructure.
The stock presents a high-risk opportunity with Wall Street maintaining bullish price targets averaging $32.75, representing 113% upside potential. However, substantial losses, negative cash flow, and competitive pressures in the AI infrastructure space create significant execution risk. Investors must weigh analyst optimism against fundamental weaknesses and market volatility.
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, though recent earnings beats in Q4 2025 and Q2 2026 show some operational resilience. Analyst consensus is mixed with a $33.14 price target, and the firm continues expanding its ETF suite, including the recent launch of the Invesco Nasdaq International Innovators 100 ETF.
The outlook remains cautious due to negative profitability margins and bearish technicals, but the absence of sell ratings and a dividend payment provide some support. Key risks include sustained negative net income and competitive pressures in the asset management sector, while potential upside hinges on improved earnings and AUM growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
